Results 91 to 100 of about 3,843,014 (290)

The effect of transfusion of blood products on ventricular assist device support outcomes

ESC Heart Failure, 2020
Aims Perioperative blood transfusions are common among patients undergoing left ventricular assist device (LVAD) implantation. The association between blood product transfusion at the time of LVAD implantation and mortality has not been described ...
Supriya Shore, Thomas C. Hanff, Jeremy A. Mazurek, Matthew Seigerman, Robert Zhang, Edward W. Grandin, Esther Vorovich, Paul Mather, Caroline Olt, Jessica Howard, Joyce Wald, Michael A. Acker, Lee R. Goldberg, Pavan Atluri, Kenneth B. Margulies, J. Eduardo Rame, Edo Y. Birati   +16 more
doaj   +1 more source

Left Ventricular Assist Device Implantation After Intracardiac Parachute Device Removal

, 2015
Left ventricular assist device implantation is a proven and efficient modality for the treatment of end-stage heart failure. Left ventricular assist device versatility as a bridge to heart transplantation or destination therapy has led to improved ...
Abu Saleh, Walid K, Al Jabbari, Odeaa, Suarez, Erik E, Bruckner, Brian A, Loebe, Matthias, Estep, Jerry D   +5 more
core   +1 more source

SR‐A3 Promotes USP18‐Mediated deISGylation of STING to Protect Against Myocardial Ischemia‐Reperfusion Injury

Advanced Science, EarlyView.
MI/RI is a major clinical challenge with high morbidity and mortality. This study demonstrates that SR‐A3 expression is downregulated in MI/RI, and its deletion exacerbates damage via the USP18/ISG15/STING axis, revealing SR‐A3 as a potential therapeutic target.
Yufei Han, Guolin Miao, Yinqi Zhao, Zhiyong Du, Kaikai Lu, Changqi Xiao, Aiden Xian, Jiaxin Duanmu, Zihao Zhou, Jinxuan Chen, Lianxin Zhang, Chao Zhai, Yitong Xu, Zhaoling Li, Xianqin Shen, Sijing Shi, Jingxuan Chen, Si Mei, Yuan Fang, Liwen Zheng, Ling Zhang, Yuhui Wang, Wei Huang, Erdan Dong, Xunde Xian   +24 more
wiley   +1 more source

Intensive care experiences of patients with implanted left ventricular assist devices: a qualitative study

BMC Cardiovascular Disorders
Background Patients with left ventricular assist device implants experience unique physical, emotional, and psychosocial experiences during their intensive care unit period.
Nihal Celikturk Doruker
doaj   +1 more source

Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting

Advanced Science, EarlyView.
Cardiovascular risk often persists after metabolic abnormalities are corrected. This conceptual Review frames such persistence as metabolic memory, encoded through a narrowing therapeutic window from reversible marks to irreversible damage, with continuous input from peripheral organs.
Cheng Cheng, Minghui Tang, Zhaobo Zhang, Ruoyi Qu, Jianfei Pei, Tian Liu, Siyao Qu, Shilong You, Shenshen Cui, Wenke Wang, Rui Zhao, Yingxian Sun, Naijin Zhang   +12 more
wiley   +1 more source

Surgical Outcomes of Centrifugal Continuous-Flow Implantable Left Ventricular Assist Devices: Heartmate 3 versus Heartware Ventricular Assist Device

Journal of Chest Surgery
Background: Left ventricular assist devices (LVADs) are widely employed as a therapeutic option for end-stage heart failure. We evaluated the outcomes associated with centrifugal- flow LVAD implantation, comparing 2 device models: the Heartmate 3 (HM3)
Kinam Shin, Won Chul Cho, Nara Shin, Hong Rae Kim, Min-Seok Kim, Cheol Hyun Chung, Sung-Ho Jung   +6 more
doaj   +1 more source

Left Ventricular Assist Device-Associated Infections: Case Series

Journal of Global Antimicrobial Resistance
AIM: We evaluate the epidemiological, laboratory, and clinical data of left ventricular assist device (LVAD)-associated infections diagnosed based on clinical evaluation, imaging studies, and microbiologic tests.
Bahar Busra Sivrikaya, Ozgur Gunal
doaj   +1 more source

Pulsus Alternans as a Sign of Right Ventricular Failure After Left Ventricular Assist Device Implantation

, 2020
Temporary left ventricular assist devices such as the ImpellaTM are increasingly used in patients with cardiogenic shock. The right ventricle remains the Achilles heel of left ventricular assist device-supported circulation.
Rega, Filip, Balthazar, Tim, Adriaenssens, Tom, Vandenbriele, Christophe   +3 more
core   +1 more source

CAR‐Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune‐Mediated Inflammation

Advanced Science, EarlyView.
CAR‐engineered cell therapies are expanding beyond cancer toward immune resetting, pathological‐cell clearance, matrix remodeling, and microenvironmental reprogramming in autoimmune, inflammatory, and fibrotic diseases. This Review compares CAR‐T, CAR‐macrophage, and CAR‐NK platforms and proposes controllable spatiotemporal reprogramming to align ...
Peng Jun Xu, Zhou Jing Zhang, Jing Jin, Hai Yuan Xu, Ya Xin Gu, Qian Qian Yang, You Lang Zhou   +6 more
wiley   +1 more source

Emergent decommissioning of HeartMate 3 for life-threatening hemorrhage

Journal of Vascular Surgery Cases and Innovative Techniques
Left ventricular assist devices are known for the treatment of heart failure. We present a patient who underwent emergent decommissioning of his left ventricular assist device after experiencing life-threatening hemorrhage.
Reginald E. Du, MD, Ryan S. Bedi, MD, W. Charles Sternbergh, III, MD, Aditya Bansal, MD   +3 more
doaj   +1 more source